| Year |
Citation |
Score |
| 2023 |
Benzidia I, Robitaille C, Abualsaud A, McDonald L, Lesenko L, Morin JF, Langleben D, Kahn SR, Hirsch A. Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension. Thrombosis Research. 229: 139-145. PMID 37453256 DOI: 10.1016/j.thromres.2023.07.002 |
0.405 |
|
| 2022 |
Benza RL, Langleben D, Hemnes AR, Vonk Noordegraaf A, Rosenkranz S, Thenappan T, Hassoun PM, Preston IR, Ghio S, Badagliacca R, Vizza CD, Lang IM, Meier C, Grünig E. Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Review : An Official Journal of the European Respiratory Society. 31. PMID 36198418 DOI: 10.1183/16000617.0061-2022 |
0.48 |
|
| 2022 |
Langleben D, Orfanos SE, Fox BD, Messas N, Giovinazzo M, Catravas JD. The Paradox of Pulmonary Vascular Resistance: Restoration of Pulmonary Capillary Recruitment as a for True Therapeutic Success in Pulmonary Arterial Hypertension. Journal of Clinical Medicine. 11. PMID 35956182 DOI: 10.3390/jcm11154568 |
0.511 |
|
| 2022 |
Humbert M, Simonneau G, Pittrow D, Delcroix M, Pepke-Zaba J, Langleben D, Mielniczuk LM, Escribano Subias P, Snijder RJ, Barberà JA, Klotsche J, Meier C, Hoeper MM. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 41: 716-721. PMID 35305871 DOI: 10.1016/j.healun.2022.02.002 |
0.36 |
|
| 2021 |
Benza RL, Ghofrani HA, Grünig E, Hoeper MM, Jansa P, Jing ZC, Kim NH, Langleben D, Simonneau G, Wang C, Busse D, Meier C, Ghio S. Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. PMID 34353714 DOI: 10.1016/j.healun.2021.06.020 |
0.533 |
|
| 2021 |
Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, Grünig E, Jansa P, Klinger JR, Langleben D, McLaughlin VV, Meyer GMB, Ota-Arakaki J, Peacock AJ, Pulido T, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. The Lancet. Respiratory Medicine. PMID 33773120 DOI: 10.1016/S2213-2600(20)30532-4 |
0.439 |
|
| 2020 |
Ghofrani HA, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, et al. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine. 178: 106220. PMID 33540340 DOI: 10.1016/j.rmed.2020.106220 |
0.495 |
|
| 2020 |
Hoeper MM, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, et al. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine. 177: 106241. PMID 33422952 DOI: 10.1016/j.rmed.2020.106241 |
0.513 |
|
| 2020 |
Simonneau G, Ghofrani HA, Corris PA, Rosenkranz S, Grünig E, White J, McLaughlin VV, Langleben D, Meier C, Busse D, Kleinjung F, Benza RL. Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. Pulmonary Circulation. 10: 2045894020973124. PMID 33354316 DOI: 10.1177/2045894020973124 |
0.455 |
|
| 2020 |
Klinger JR, Chakinala MM, Langleben D, Rosenkranz S, Sitbon O. Riociguat: clinical research and evolving role in therapy. British Journal of Clinical Pharmacology. PMID 33242341 DOI: 10.1111/bcp.14676 |
0.472 |
|
| 2020 |
Ghofrani HA, Grünig E, Jansa P, Langleben D, Rosenkranz S, Preston IR, Rahaghi F, Sood N, Busse D, Meier C, Humbert M. Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). Pulmonary Circulation. 10: 2045894020942121. PMID 32728421 DOI: 10.1177/2045894020942121 |
0.461 |
|
| 2020 |
Vassiliou AG, Keskinidou C, Kotanidou A, Frantzeskaki F, Dimopoulou I, Langleben D, Orfanos SE. Knockdown of bone morphogenetic protein type II receptor leads to decreased aquaporin 1 expression and function in human pulmonary microvascular endothelial cells. Canadian Journal of Physiology and Pharmacology. 98: 834-839. PMID 32687728 DOI: 10.1139/cjpp-2020-0185 |
0.312 |
|
| 2020 |
Hirani N, Brunner NW, Kapasi A, Chandy G, Rudski L, Paterson I, Langleben D, Mehta S, Mielniczuk L. Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. The Canadian Journal of Cardiology. 36: 977-992. PMID 32682511 DOI: 10.1016/J.Cjca.2019.11.041 |
0.454 |
|
| 2020 |
Benza RL, Corris PA, Klinger JR, Langleben D, Naeije R, Simonneau G, Ghofrani HA, Jansa P, Rosenkranz S, Scelsi L, Thenappan T, Raina A, Meier C, Busse D, Hoeper MM. Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. International Journal of Cardiology. 317: 188-192. PMID 32461118 DOI: 10.1016/J.Ijcard.2020.05.044 |
0.429 |
|
| 2020 |
Semalulu T, Rudski L, Huynh T, Langleben D, Wang M, Fritzler MJ, Pope J, Baron M, Hudson M. An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. Seminars in Arthritis and Rheumatism. PMID 32245697 DOI: 10.1016/J.Semarthrit.2020.02.013 |
0.504 |
|
| 2020 |
Langleben D, Channick R, Delcroix M, Galiè N, Ghofrani A, Jansa P, Mehta S, Pulido T, Souza R, Simonneau G, Sastry BKS, Torbicki A, Martin N, Perchenet L, Sitbon O. Safety And Efficacy Of Macitentan In Elderly Patients With Pulmonary Arterial Hypertension (Pah): Insights From Seraphin Journal of the American College of Cardiology. 75: 2090. DOI: 10.1016/S0735-1097(20)32717-0 |
0.479 |
|
| 2020 |
Vassiliou AG, Keskinidou C, Kotanidou A, Frantzeskaki F, Dimopoulou I, Langleben D, Orfanos SE. Decreased bone morphogenetic protein type II receptor and BMP-related signalling molecules' expression in aquaporin 1-silenced human pulmonary microvascular endothelial cells. Hellenic Journal of Cardiology. DOI: 10.1016/J.Hjc.2020.04.003 |
0.338 |
|
| 2019 |
Moghaddam N, Swiston JR, Weatherald J, Mielniczuk L, Kapasi A, Hambly N, Langleben D, Brunner NW. Impact of saline loading at cardiac catheterization on the classification and management of patients evaluated for pulmonary hypertension. International Journal of Cardiology. PMID 31784045 DOI: 10.1016/J.Ijcard.2019.11.104 |
0.434 |
|
| 2019 |
McLaughlin VV, Channick R, De Marco T, Farber HW, Gaine S, Galié N, Krasuski RA, Preston I, Souza R, Coghlan JG, Frantz RP, Hemnes A, Kim NH, Lang IM, Langleben D, et al. Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents. Chest. PMID 31738929 DOI: 10.1016/J.Chest.2019.10.043 |
0.507 |
|
| 2019 |
Langleben D, Orfanos SE, Giovinazzo M, Schlesinger RD, Naeije R, Fox BD, Abualsaud AO, Blenkhorn F, Rudski LG, Catravas JD. Pulmonary capillary surface area in supine exercising humans: demonstration of vascular recruitment. American Journal of Physiology. Lung Cellular and Molecular Physiology. PMID 31242024 DOI: 10.1152/Ajplung.00098.2019 |
0.404 |
|
| 2019 |
Langleben D, Gaine S, Sitbon O, Channick R, Chin K, Scala LD, Galiè N, Hoeper M, McLaughlin V, Preiss R, Rubin L, Simonneau G, Tapson V, Ghofrani H, Lang I. The Impact Of Time From Diagnosis At Baseline On Long-Term Outcome In The Griphon Study: Selexipag In Pulmonary Arterial Hypertension (Pah) Canadian Journal of Cardiology. 35. DOI: 10.1016/J.Cjca.2019.07.180 |
0.504 |
|
| 2019 |
McLaughlin V, Channick R, Marco TD, Farber H, Gaine S, Galie N, Krasuski R, Preston I, Souza R, Coghlan J, Frantz R, Hemnes A, Kim N, Lang I, Langleben D, et al. Prostacyclin International Expert Panel Consensus-Based Recommendations For The Use Of Selexipag In Patients With Pulmonary Arterial Hypertension Chest. 156. DOI: 10.1016/J.Chest.2019.08.1023 |
0.572 |
|
| 2018 |
Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, Kawut SM, Langleben D, Lumens J, Naeije R. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. The European Respiratory Journal. PMID 30545976 DOI: 10.1183/13993003.01900-2018 |
0.438 |
|
| 2018 |
Langleben D, Orfanos SE. Pulmonary capillary recruitment in exercise and pulmonary hypertension. The European Respiratory Journal. 51. PMID 29545319 DOI: 10.1183/13993003.02559-2017 |
0.505 |
|
| 2018 |
Benza R, Ghio S, Grünig E, Jing Z, Langleben D, Ghofrani H, Meier C, Busse D. Effect Of Riociguat On Right Ventricular Function In Patients With Pulmonary Arterial Hypertension Chest. 154. DOI: 10.1016/J.Chest.2018.08.962 |
0.574 |
|
| 2017 |
Benza RL, Farber HW, Frost AE, Ghofrani HA, Gómez-Sánchez MA, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper MM. REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. Journal of Heart and Lung Transplantation. 37: 513-519. PMID 29223470 DOI: 10.1016/J.Healun.2017.11.006 |
0.348 |
|
| 2017 |
Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. The European Respiratory Journal. 50. PMID 28889107 DOI: 10.1183/13993003.02425-2016 |
0.465 |
|
| 2017 |
Langleben D, Orfanos S. Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis. Pulmonary Circulation. 7: 588-597. PMID 28632001 DOI: 10.1177/2045893217714231 |
0.534 |
|
| 2017 |
Zhan Y, Burstein B, Abualsaud AO, Nosair M, Hirsch AM, Lesenko L, Langleben D. Right ventricular ST-elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension. Pulmonary Circulation. 7: 555-558. PMID 28597772 DOI: 10.1177/2045893217704435 |
0.419 |
|
| 2017 |
Harel F, Langleben D, Provencher S, Fournier A, Finnerty V, Nguyen QT, Letourneau M, Levac X, Abikhzer G, Guimond J, Mansour A, Guertin MC, Dupuis J. Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. European Journal of Nuclear Medicine and Molecular Imaging. PMID 28236024 DOI: 10.1007/s00259-017-3655-y. |
0.526 |
|
| 2017 |
Gall H, Ghofrani H, Humbert M, Simonneau G, Grünig E, Klose H, Halank M, Langleben D, Mielniczuk LM, Vachiéry J, Wirtz H, Lange T, Escribano P, Helmersen DS, Pepke-Zaba J, et al. Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry European Respiratory Journal. 50. DOI: 10.1183/1393003.Congress-2017.Pa3534 |
0.516 |
|
| 2017 |
Hoeper MM, Ghofrani H, Benza RL, Corris PA, Gibbs J, Klinger JR, Langleben D, McLaughlin V, Peacock A, Rosenkranz S, Vonk-Noordegraf A, White R, Kleinjung F, Meier C, Simonneau G. REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal European Respiratory Journal. 50. DOI: 10.1183/1393003.Congress-2017.Pa2417 |
0.503 |
|
| 2017 |
Hoeper MM, Corris PA, Ghofrani H, Klinger JR, Langleben D, Naeije R, Simonneau G, Jansa P, Rosenkranz S, Grünig E, Scelsi L, Meier C, Busse D, Benza RL. Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study European Respiratory Journal. DOI: 10.1183/1393003.Congress-2017.Oa1980 |
0.59 |
|
| 2017 |
Thenappan T, Hoeper M, Corris P, Ghofrani H, Klinger J, Langleben D, Naeije R, Simonneau G, Jansa P, Rosenkranz S, Grünig E, Scelsi L, Meier C, Busse D, Benza R. Effect of Riociguat on Pulmonary Arterial Compliance in Patients With Pulmonary Arterial Hypertension (PAH) in the Respite Study Chest. 152. DOI: 10.1016/J.Chest.2017.08.1040 |
0.59 |
|
| 2016 |
Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. PMID 28190787 DOI: 10.1016/J.Healun.2016.12.012 |
0.572 |
|
| 2016 |
Hoeper MM, Klinger JR, Benza RL, Simonneau G, Langleben D, Naeije R, Corris PA. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respiratory Medicine. S18-S22. PMID 27887774 DOI: 10.1016/j.rmed.2016.11.001 |
0.397 |
|
| 2016 |
Limoges M, Langleben D, Fox BD, Shear R, Wieczorek P, Rudski LG, Hirsch AM, Schlesinger RD, Lesenko L. Pregnancy as a possible trigger for heritable pulmonary arterial hypertension. Pulmonary Circulation. 6: 381-3. PMID 27683615 DOI: 10.1086/686993 |
0.414 |
|
| 2016 |
Fox BD, Shtraichman O, Langleben D, Shimony A, Kramer MR. Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. The Canadian Journal of Cardiology. PMID 27378592 DOI: 10.1016/j.cjca.2016.03.004 |
0.454 |
|
| 2016 |
Ghofrani HA, Humbert M, Langleben D, Schermuly R, Stasch JP, Wilkins MR, Klinger JR. Riociguat: Mode of action and clinical development in pulmonary hypertension. Chest. PMID 27263466 DOI: 10.1016/J.Chest.2016.05.024 |
0.568 |
|
| 2016 |
Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Humbert M. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. The Lancet. Respiratory Medicine. PMID 27067479 DOI: 10.1016/S2213-2600(16)30019-4 |
0.517 |
|
| 2016 |
Dupuis J, Harel F, Langleben D, Provencher S, Fournier A, Nguyen QT, Finnerty V, Letourneau M, Levac X, Mansour A, Abikhzer G, Guimond J. MOLECULAR IMAGING OF THE HUMAN PULMONARY VASCULAR ENDOTHELIUM IN PULMONARY HYPERTENSION: THE PULMOBIND SAFETY AND PROOF OF PRINCIPLE TRIAL Journal of the American College of Cardiology. 67: 2045. DOI: 10.1016/S0735-1097(16)32046-0 |
0.508 |
|
| 2016 |
Granton J, Bergot E, Boonstra A, Subias PE, Galiè N, Langleben D, Lemarié JC, Pfister T, Simonneau G, Sitbon O, Delcroix M. Long-Term Safety and Tolerability of a New Formulation of Epoprostenol in Pulmonary Arterial Hypertension (PAH) Patients: Final Results from EPITOME-2 Journal of Heart and Lung Transplantation. 35. DOI: 10.1016/J.Healun.2016.01.1031 |
0.534 |
|
| 2016 |
Langleben D, Beghetti M, Channick R, Chin K, DiScala L, Gaine S, Ghofrani H, Hoeper M, Lang I, McLaughlin V, Preiss R, Rubin L, Simonneau G, Sitbon O, Tapson V, et al. Selexipag For Pulmonary Arterial Hypertension Associated With Congenital Heart Disease (Pah-Chd) After Defect Correction: Insights From The Randomised Controlled Griphon Study Canadian Journal of Cardiology. 32. DOI: 10.1016/J.Cjca.2016.07.251 |
0.503 |
|
| 2015 |
Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, Langleben D, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK. ET-1 Pathway Polymorphisms Affect Outcome in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. PMID 26252367 DOI: 10.1164/Rccm.201501-0196Oc |
0.448 |
|
| 2015 |
Granton J, Langleben D, Kutryk MB, Camack N, Galipeau J, Courtman DW, Stewart DJ. Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. Circulation Research. 117: 645-54. PMID 26195220 DOI: 10.1161/Circresaha.114.305951 |
0.546 |
|
| 2015 |
Afilalo J, Grapsa J, Nihoyannopoulos P, Beaudoin J, Gibbs JS, Channick RN, Langleben D, Rudski LG, Hua L, Handschumacher MD, Picard MH, Levine RA. Leaflet area as a determinant of tricuspid regurgitation severity in patients with pulmonary hypertension. Circulation. Cardiovascular Imaging. 8. PMID 25977303 DOI: 10.1161/Circimaging.114.002714 |
0.402 |
|
| 2015 |
Fox BD, Joyal D, Schlesinger RD, Eisenberg MJ, Langleben D. Evaluation of the Microstat™ sublingual PCO2 monitor in ambulatory patients. Journal of Clinical Monitoring and Computing. PMID 25753144 DOI: 10.1007/S10877-015-9686-7 |
0.381 |
|
| 2015 |
Langleben D, Galiè N, He J, Huang Y, Humbert M, Keogh A, Rubin LJ, Zhou D, Curram J, Davie N, Ghofrani HA. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 34: 338-47. PMID 25703961 DOI: 10.1016/J.Healun.2014.12.001 |
0.512 |
|
| 2015 |
Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A, Menezes F, Davie N, Ghofrani HA. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). The European Respiratory Journal. 45: 1303-13. PMID 25614164 DOI: 10.1183/09031936.00090614 |
0.554 |
|
| 2015 |
Langleben D, Orfanos SE, Giovinazzo M, Schlesinger RD, Hirsch AM, Blenkhorn F, Lesenko L, Armaganidis A, Catravas JD. Acute vasodilator responsiveness and microvascular recruitment in idiopathic pulmonary arterial hypertension. Annals of Internal Medicine. 162: 154-6. PMID 25599356 DOI: 10.7326/M14-1402 |
0.555 |
|
| 2015 |
Benza R, Frost A, Farber H, Ghofrani HA, Gómez-Sánchez M, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper M. Application of REVEAL Risk Score to Patients With PAH Receiving Riociguat in the PATENT-2 Study Chest. 148. DOI: 10.1378/Chest.2280692 |
0.301 |
|
| 2015 |
Hoeper M, Benza R, Klinger J, Simonneau G, Langleben D, Naeije R, Corris P. Rationale and Study Design of the RESPITE Trial: Riociguat Clinical Effects Studied in Pulmonary Arterial Hypertension (PAH) Patients With Insufficient Treatment Response to PDE-5 Inhibitors (PDE-5i) Chest. 148. DOI: 10.1378/Chest.2272572 |
0.535 |
|
| 2014 |
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. [Definitions and diagnosis of pulmonary hypertension]. TüRk Kardiyoloji DerneğI ArşIvi : TüRk Kardiyoloji DerneğInin YayıN OrganıDıR. 42: 55-66. PMID 25697034 |
0.441 |
|
| 2014 |
Fox BD, Azoulay L, Dell'Aniello S, Langleben D, Lapi F, Benisty J, Suissa S. The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension. The Canadian Journal of Cardiology. 30: 1633-9. PMID 25448462 DOI: 10.1016/j.cjca.2014.09.031 |
0.433 |
|
| 2014 |
Rudski LG, Bossone E, Langleben D. From the echo bed to the pulmonary vascular bed: dobutamine testing in the noninvasive laboratory. Chest. 146: 876-878. PMID 25287995 DOI: 10.1378/chest.14-0856 |
0.326 |
|
| 2014 |
Star GP, Giovinazzo M, Lamoureux E, Langleben D. Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro. Life Sciences. 118: 191-4. PMID 24607779 DOI: 10.1016/J.Lfs.2014.02.032 |
0.385 |
|
| 2014 |
Shimony A, Afilalo J, Flynn AW, Langleben D, Agnihotri AK, Morin JF, Shahian DM, Picard MH, Rudski LG. Usefulness of right ventricular dysfunction to predict new-onset atrial fibrillation following coronary artery bypass grafting. The American Journal of Cardiology. 113: 913-8. PMID 24440329 DOI: 10.1016/J.Amjcard.2013.11.048 |
0.308 |
|
| 2014 |
Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, Subías PE, Galiè N, Pfister T, Lemarié J, Simonneau G. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension American Heart Journal. 167: 210-217. PMID 24439982 DOI: 10.1016/J.Ahj.2013.08.007 |
0.469 |
|
| 2013 |
Guo K, Langleben D, Afilalo J, Shimony A, Leask R, Marelli A, Martucci G, Therrien J. Anatomical considerations for the development of a new transcatheter aortopulmonary shunt device in patients with severe pulmonary arterial hypertension. Pulmonary Circulation. 3: 639-46. PMID 24618548 DOI: 10.1086/674328 |
0.445 |
|
| 2013 |
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. Journal of the American College of Cardiology. 62: D42-50. PMID 24355641 DOI: 10.1016/j.jacc.2013.10.032 |
0.442 |
|
| 2013 |
Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis and Rheumatism. 65: 3194-201. PMID 24022584 DOI: 10.1002/Art.38172 |
0.413 |
|
| 2013 |
Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ. Riociguat for the treatment of pulmonary arterial hypertension. The New England Journal of Medicine. 369: 330-40. PMID 23883378 DOI: 10.1056/Nejmoa1209655 |
0.564 |
|
| 2013 |
Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, Eisenberg MJ, Joyal D, Hudson M, Boutet K, Serban A, Masetto A, Baron M. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. The European Respiratory Journal. 42: 1083-91. PMID 23258775 DOI: 10.1183/09031936.00091212 |
0.502 |
|
| 2013 |
Star GP, Giovinazzo M, Langleben D. ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells. Microvascular Research. 85: 46-53. PMID 23142694 DOI: 10.1016/J.Mvr.2012.10.012 |
0.353 |
|
| 2013 |
Fox BD, Langleben D, Hirsch A, Boutet K, Shimony A. Step climbing capacity in patients with pulmonary hypertension. Clinical Research in Cardiology : Official Journal of the German Cardiac Society. 102: 51-61. PMID 22875547 DOI: 10.1007/S00392-012-0495-4 |
0.533 |
|
| 2013 |
Fox B, Langleben D, Hirsch AM, Schlesinger RD, Eisenberg MJ, Joyal D, Blenkhorn F, Lesenko L. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension. The Canadian Journal of Cardiology. 29: 672-7. PMID 22819360 DOI: 10.1016/J.Cjca.2012.05.013 |
0.537 |
|
| 2013 |
Shimony A, Fox BD, Langleben D, Rudski LG. Incidence and significance of pericardial effusion in patients with pulmonary arterial hypertension. The Canadian Journal of Cardiology. 29: 678-82. PMID 22717247 DOI: 10.1016/J.Cjca.2012.04.009 |
0.57 |
|
| 2013 |
Jing Z-, Galie N, Ghofrani H-, Humbert M, Langleben D, Rubin LJ, Hoeper MM, Fritsch A, Davie N, Keogh AM. Comparison of hemodynamic parameters in treatment-naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT-1 study European Heart Journal. 34: 323. DOI: 10.1093/Eurheartj/Eht307.P323 |
0.386 |
|
| 2013 |
Langleben D. The evolving paradigm of pulmonary arterial hypertension and the evolving role of endothelin-1 Life Sciences. 93. DOI: 10.1016/J.Lfs.2013.12.113 |
0.574 |
|
| 2012 |
Shimony A, Fox BD, Afilalo J, Rudski LG, Hirsch A, Langleben D. Pulmonary arterial hypertension in the elderly-clinical characteristics and long-term survival. Lung. 190: 645-9. PMID 23064491 DOI: 10.1007/s00408-012-9425-5 |
0.428 |
|
| 2012 |
Fox BD, Shimony A, Langleben D. Combination therapy in pulmonary arterial hypertension. Cardiology. 123: 41; author reply 42. PMID 22986302 DOI: 10.1159/000342061 |
0.468 |
|
| 2012 |
Ghofrani H, Galie N, Grimminger F, Humbert M, Keogh A, Langleben D, Kilama MO, Neuser D, Rubin L. Riociguat for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (PATENT-1) Chest. 142. DOI: 10.1378/Chest.1462799 |
0.545 |
|
| 2011 |
Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. The American Journal of Cardiology. 108: 1177-82. PMID 21864815 DOI: 10.1016/J.Amjcard.2011.06.021 |
0.39 |
|
| 2011 |
Shimony A, Eisenberg MJ, Rudski LG, Schlesinger R, Afilalo J, Joyal D, Dragatakis L, Hirsch A, Boutet K, Fox BD, Langleben D. Prevalence and impact of coronary artery disease in patients with pulmonary arterial hypertension. The American Journal of Cardiology. 108: 460-4. PMID 21600533 DOI: 10.1016/J.Amjcard.2011.03.066 |
0.487 |
|
| 2010 |
Langleben D, Orfanos SE. Systemic sclerosis and early-onset pulmonary hypertension. Chest. 138: 238-9. PMID 20605834 DOI: 10.1378/chest.10-0501 |
0.393 |
|
| 2010 |
Star GP, Giovinazzo M, Langleben D. Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: A potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension Microvascular Research. 80: 349-354. PMID 20594999 DOI: 10.1016/J.Mvr.2010.05.010 |
0.419 |
|
| 2010 |
Corris PA, Langleben D. The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension. The European Respiratory Journal. 35: 460-1; author reply . PMID 20123858 DOI: 10.1183/09031936.00160309 |
0.461 |
|
| 2010 |
Orfanos SE, Langleben D. Pulmonary arterial hypertension in systemic sclerosis: a distinctive endotheliopathy? The European Respiratory Journal. 35: 223-4. PMID 20044465 DOI: 10.1183/09031936.00130409 |
0.46 |
|
| 2010 |
Langleben D. Pulmonary capillary haemangiomatosis. British Heart Journal. 62: 239. PMID 18610363 DOI: 10.1136/hrt.62.3.239 |
0.447 |
|
| 2009 |
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. 54: S43-54. PMID 19555858 DOI: 10.1016/j.jacc.2009.04.012 |
0.434 |
|
| 2009 |
Langleben D, Cacoub P. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. European Journal of Clinical Investigation. 27-31. PMID 19335744 DOI: 10.1111/j.1365-2362.2009.02118.x |
0.405 |
|
| 2009 |
Star GP, Giovinazzo M, Langleben D. Effects of bone morphogenic proteins and transforming growth factor-beta on In-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells Vascular Pharmacology. 50: 45-50. PMID 18849010 DOI: 10.1016/J.Vph.2008.09.001 |
0.329 |
|
| 2008 |
Orfanos SE, Hirsch AM, Giovinazzo M, Armaganidis A, Catravas JD, Langleben D. Pulmonary capillary endothelial metabolic function in chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Haemostasis : Jth. 6: 1275-80. PMID 18532994 DOI: 10.1111/J.1538-7836.2008.03046.X |
0.548 |
|
| 2008 |
Langleben D, Orfanos SE, Giovinazzo M, Hirsch A, Baron M, Senécal JL, Armaganidis A, Catravas JD. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis and Rheumatism. 58: 1156-64. PMID 18383374 DOI: 10.1002/Art.23405 |
0.573 |
|
| 2008 |
Cacoub P, Amoura Z, Langleben D. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008]. La Revue De Medecine Interne. 29: 283-9. PMID 18243424 DOI: 10.1016/j.revmed.2007.12.005 |
0.501 |
|
| 2007 |
Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Annals of the Rheumatic Diseases. 66: 1467-72. PMID 17472992 DOI: 10.1136/Ard.2007.069609 |
0.458 |
|
| 2007 |
Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clinics in Chest Medicine. 28: 117-125. PMID 17338931 DOI: 10.1016/J.Ccm.2006.11.002 |
0.528 |
|
| 2007 |
Hooper WC, Mensah GA, Haworth SG, Black SM, Garcia JGN, Langleben D. Vascular endothelium summary statement V: Pulmonary hypertension and acute lung injury: public health implications. Vascular Pharmacology. 46: 327-329. PMID 17197249 DOI: 10.1016/J.Vph.2006.10.017 |
0.498 |
|
| 2006 |
Therrien J, Rambihar S, Newman B, Siminovitch K, Langleben D, Webb G, Granton J. Eisenmenger syndrome and atrial septal defect: nature or nurture? The Canadian Journal of Cardiology. 22: 1133-6. PMID 17102831 |
0.401 |
|
| 2006 |
Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. American Heart Journal. 152: 521-6. PMID 16923424 DOI: 10.1016/J.Ahj.2006.02.020 |
0.522 |
|
| 2006 |
Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. Journal of the American College of Cardiology. 47: 2049-56. PMID 16697324 DOI: 10.1016/j.jacc.2006.01.057 |
0.441 |
|
| 2006 |
Langleben D, Dupuis J, Langleben I, Hirsch AM, Baron M, Senécal JL, Giovinazzo M. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest. 129: 689-95. PMID 16537869 DOI: 10.1378/Chest.129.3.689 |
0.422 |
|
| 2006 |
Langleben D, Dupuis J, Hirsch A, Giovinazzo M, Langleben I, Khoury J, Ruel N, Caron A. Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. Chest. 128: 622S. PMID 16373881 DOI: 10.1378/chest.128.6_suppl.622S |
0.506 |
|
| 2006 |
Benisty JI, Folkman J, Zurakowski D, Louis G, Rich S, Langleben D, Moses MA. Matrix metalloproteinases in the urine of patients with pulmonary arterial hypertension. Chest. 128: 572S. PMID 16373832 DOI: 10.1378/chest.128.6_suppl.572S |
0.47 |
|
| 2005 |
Langleben D, Archer S, Granton J, Hirsch AM, Levy RD, Mehta S, Michelakis E, Stewart DJ. Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. Canadian Respiratory Journal : Journal of the Canadian Thoracic Society. 12: 303-15. PMID 16247528 DOI: 10.1155/2005/156750 |
0.529 |
|
| 2005 |
Langleben D, Archer S, Granton J, Hirsch AM, Levy RD, Mehta S, Michelakis E, Stewart DJ. Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. The Canadian Journal of Cardiology. 21: 909-14. PMID 16239973 |
0.445 |
|
| 2005 |
Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, Robbins IM, Shapiro S, Tapson VF, Zwicke D, DeMarco T, Schilz R, Rubenfire M, Barst RJ. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascular Pharmacology. 43: 36-9. PMID 15890561 DOI: 10.1016/j.vph.2005.03.003 |
0.437 |
|
| 2005 |
Seibold J, Badesch D, Galie N, Langleben D, Naeije R, Simonneau G, Barst R. Sitaxsentan, A Selective Endothelin-A Receptor Antagonist, Improves Exercise Capacity In Pulmonary Arterial Hypertension (Pah) Associated With Connective Tissue Disease (Ctd) Chest. 128. DOI: 10.1378/Chest.128.4_Meetingabstracts.219S |
0.497 |
|
| 2005 |
Badesch D, Galie N, Langleben D, Naeije R, Simonneau G, Barst R. Sitaxsentan Improves Time To Clinical Worsening In Patients With Pulmonary Arterial Hypertension Chest. 128. DOI: 10.1378/Chest.128.4_Meetingabstracts.160S-B |
0.571 |
|
| 2004 |
Langleben D, Brock T, Dixon R, Barst R. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. Journal of Cardiovascular Pharmacology. 44: S80-4. PMID 15838366 DOI: 10.1097/01.Fjc.0000166207.74178.D0 |
0.489 |
|
| 2004 |
Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 126: 1377-81. PMID 15486408 DOI: 10.1378/Chest.126.4.1377 |
0.546 |
|
| 2004 |
Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. 43: 5S-12S. PMID 15194173 DOI: 10.1016/j.jacc.2004.02.037 |
0.475 |
|
| 2004 |
Langleben D. Clinical relevance of endothelin B-mediated vasoconstriction in lambs with increased pulmonary blood flow. Circulation. 109. PMID 15078812 DOI: 10.1161/01.Cir.0000124886.51828.E6 |
0.364 |
|
| 2004 |
Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR. Sitaxsentan therapy for pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 169: 441-7. PMID 14630619 DOI: 10.1164/Rccm.200307-957Oc |
0.487 |
|
| 2004 |
McLaughlin VV, Hill N, Tapson V, Frost A, Langleben D, Oudiz R, Shapiro S, Robbins I, Barst RJ. Sitaxsentan Improves 6MW in Patients with Pulmonary Arterial Hypertension (PAH) Related to Connective-Tissue Diseases (CTD) Chest. 126: 7-9. DOI: 10.1378/Chest.126.4_Meetingabstracts.759S-A |
0.553 |
|
| 2004 |
Langleben D, Hirsch A, Shalit E, Lesenko L, Barst RJ, Davis MB. 1123-183 Sustained hemodynamic benefit in patients with pulmonary arterial hypertension after one-year of therapy with the selective orally-active endothelin-A receptor antagonist, sitaxsentan Journal of the American College of Cardiology. 43. DOI: 10.1016/S0735-1097(04)92122-5 |
0.529 |
|
| 2003 |
Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology. 99: 1415-1432. PMID 14639158 DOI: 10.1097/00000542-200312000-00027 |
0.563 |
|
| 2003 |
Michel RP, Langleben D, Dupuis J. The endothelin system in pulmonary hypertension. Canadian Journal of Physiology and Pharmacology. 81: 542-54. PMID 12839266 DOI: 10.1139/Y03-008 |
0.508 |
|
| 2002 |
Langleben D, Christman BW, Barst RJ, Dias VC, Galiè N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. American Heart Journal. 143: E4. PMID 12040360 DOI: 10.1067/Mhj.2002.121806 |
0.499 |
|
| 2001 |
Sebbag I, Rudski LG, Therrien J, Hirsch A, Langleben D. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension American Journal of Cardiology. 88: 1060-1063. PMID 11704014 DOI: 10.1016/S0002-9149(01)01995-6 |
0.409 |
|
| 2001 |
Orfanos SE, Psevdi E, Stratigis N, Langleben D, Catravas JD, Kyriakidis M, Moutsopoulos HM, Roussos C, Vlachoyiannopoulos PG. Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis and Rheumatism. 44: 902-11. PMID 11315930 DOI: 10.1002/1529-0131(200104)44:4<902::Aid-Anr147>3.0.Co;2-9 |
0.49 |
|
| 2000 |
Orfanos SE, Armaganidis A, Glynos C, Psevdi E, Kaltsas P, Sarafidou P, Catravas JD, Dafni UG, Langleben D, Roussos C. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation. 102: 2011-8. PMID 11034953 DOI: 10.1161/01.Cir.102.16.2011 |
0.373 |
|
| 2000 |
Khoury J, Langleben D. Heparin-like molecules inhibit pulmonary vascular pericyte proliferation in vitro American Journal of Physiology - Lung Cellular and Molecular Physiology. 279. PMID 10926548 DOI: 10.1152/Ajplung.2000.279.2.L252 |
0.409 |
|
| 2000 |
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, ... ... Langleben D, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Annals of Internal Medicine. 132: 425-34. PMID 10733441 DOI: 10.7326/0003-4819-132-6-200003210-00002 |
0.494 |
|
| 2000 |
Langleben D, Lamoureux E, Marcotte F, Schlesinger R, Dragatakis L, Crowe MJ, Langlois Y, Lemire F, White M. Mitral stenosis obscuring the diagnosis of plexogenic pulmonary arteriopathy and familial pulmonary hypertension. Thorax. 55: 247-8. PMID 10679547 DOI: 10.1136/Thorax.55.3.247 |
0.535 |
|
| 1999 |
Langleben D, Barst RJ, Badesch D, Groves BM, Tapson VF, Murali S, Bourge RC, Ettinger N, Shalit E, Clayton LM, Jöbsis MM, Blackburn SD, Crow JW, Stewart DJ, Long W. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation. 99: 3266-71. PMID 10385501 DOI: 10.1161/01.CIR.99.25.3266 |
0.456 |
|
| 1999 |
Orfanos SE, Langleben D, Khoury J, Schlesinger RD, Dragatakis L, Roussos C, Ryan JW, Catravas JD. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in humans. Circulation. 99: 1593-9. PMID 10096936 DOI: 10.1161/01.Cir.99.12.1593 |
0.442 |
|
| 1998 |
Khoury J, Langleben D. Effects of endotoxin on lung pericytes in vitro Microvascular Research. 56: 71-84. PMID 9756730 DOI: 10.1006/Mvre.1998.2085 |
0.353 |
|
| 1998 |
Langleben D. Relearning the lessons of history: anorexigens and pulmonary hypertension. Chest. 114: 55S-57S. PMID 9676629 DOI: 10.1378/chest.114.1_supplement.55s |
0.48 |
|
| 1998 |
Oelberg DA, Marcotte F, Kreisman H, Wolkove N, Langleben D, Small D. Evaluation of right ventricular systolic pressure during incremental exercise by Doppler echocardiography in adults with atrial septal defect. Chest. 113: 1459-1465. PMID 9631778 DOI: 10.1378/Chest.113.6.1459 |
0.325 |
|
| 1997 |
Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 95: 1479-86. PMID 9118516 DOI: 10.1161/01.Cir.95.6.1479 |
0.414 |
|
| 1996 |
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The New England Journal of Medicine. 334: 296-301. PMID 8532025 DOI: 10.1056/Nejm199602013340504 |
0.454 |
|
| 1995 |
Mehta S, Stewart DJ, Langleben D, Levy RD. Short-term Pulmonary Vasodilation With l-Arginine in Pulmonary Hypertension Circulation. 92: 1539-1545. PMID 7664438 DOI: 10.1161/01.Cir.92.6.1539 |
0.511 |
|
| 1994 |
Langleben D. Familial Primary Pulmonary Hypertension Chest. 105: 13. PMID 8306801 DOI: 10.1378/Chest.105.2_Supplement.13S |
0.404 |
|
| 1994 |
Langleben D, DeMarchie M, Laporta D, Spanier AH, Schlesinger RD, Stewart DJ. Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. The American Review of Respiratory Disease. 148: 1646-50. PMID 8256914 DOI: 10.1164/ajrccm/148.6_Pt_1.1646 |
0.425 |
|
| 1993 |
Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension The New England Journal of Medicine. 328: 1732-1739. PMID 8497283 DOI: 10.1056/Nejm199306173282402 |
0.583 |
|
| 1993 |
Langleben D. Reviews, Notes, and Listings: Pulmonary Medicine: The Diagnosis and Treatment of Pulmonary Hypertension Annals of Internal Medicine. 118: 656-656. DOI: 10.7326/0003-4819-118-8-199304150-00052 |
0.527 |
|
| 1991 |
Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Annals of Internal Medicine. 114: 464-469. PMID 1994793 DOI: 10.7326/0003-4819-114-6-464 |
0.507 |
|
| 1991 |
Rush C, Langleben D, Schlesinger RD, Stern J, Wang N, Lamoureux E. Lung scintigraphy in pulmonary capillary hemangiomatosis. A rare disorder causing primary pulmonary hypertension. Clinical Nuclear Medicine. 16: 913-917. PMID 1769171 DOI: 10.1097/00003072-199112000-00007 |
0.512 |
|
| 1989 |
Langleben D, Fox RB, Jones RC, Reid LM. Effects of dimethylthiourea on chronic hypoxia-induced pulmonary arterial remodelling and ventricular hypertrophy in rats. Clinical and Investigative Medicine. MéDecine Clinique Et Experimentale. 12: 235-40. PMID 2535591 |
0.392 |
|
| 1989 |
Lisbona R, Hakim TS, Dean GW, Langleben D, Guerraty A, Levy RD. Regional pulmonary perfusion following human heart-lung transplantation. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 30: 1297-301. PMID 2502608 |
0.312 |
|
| 1988 |
Langleben D, Heneghan JM, Batten AP, Wang NS, Fitch N, Schlesinger RD, Guerraty A, Rouleau JL. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Annals of Internal Medicine. 109: 106-9. PMID 3382104 DOI: 10.7326/0003-4819-109-2-106 |
0.481 |
|
| 1988 |
Langleben D, Szarek JL, Coflesky JT, Jones RC, Reid LM, Evans JN. Altered artery mechanics and structure in monocrotaline pulmonary hypertension Journal of Applied Physiology. 65: 2326-2331. PMID 3145283 |
0.402 |
|
| 1987 |
Langleben D, Jones RC, Aronovitz MJ, Hill NS, Ou LC, Reid LM. Pulmonary artery structural changes in two colonies of rats with different sensitivity to chronic hypoxia. The American Journal of Pathology. 128: 61-6. PMID 3605313 |
0.378 |
|
| 1986 |
Langleben D, Moroz LA, McGregor M, Lisbona R. Decreased half-life of fibrinogen in primary pulmonary hypertension. Thrombosis Research. 40: 577-80. PMID 4082127 DOI: 10.1016/0049-3848(85)90295-6 |
0.507 |
|
| 1986 |
Langleben D, Carvalho AC, Reid LM. The platelet thromboxane inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension. The American Review of Respiratory Disease. 133: 789-91. PMID 3085563 |
0.319 |
|
| 1985 |
Geggel RL, Murphy JD, Langleben D, Crone RK, Vacanti JP, Reid LM. Congenital diaphragmatic hernia: arterial structural changes and persistent pulmonary hypertension after surgical repair. The Journal of Pediatrics. 107: 457-64. PMID 4032138 DOI: 10.1016/S0022-3476(85)80534-5 |
0.319 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 1985 |
Langleben D, Reid LM. Effect of methylprednisolone on monocrotaline-induced pulmonary vascular disease and right ventricular hypertrophy. Laboratory Investigation; a Journal of Technical Methods and Pathology. 52: 298-303. PMID 3156262 |
0.3 |
|
| 2022 |
Vrigkou E, Vassilatou E, Dima E, Langleben D, Kotanidou A, Tzanela M. The Role of Thyroid Disorders, Obesity, Diabetes Mellitus and Estrogen Exposure as Potential Modifiers for Pulmonary Hypertension. Journal of Clinical Medicine. 11. PMID 35207198 DOI: 10.3390/jcm11040921 |
0.299 |
|
| 2014 |
Meyer G, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani H. Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension Chest. 145: 513. DOI: 10.1378/Chest.1824389 |
0.296 |
|
| 2017 |
Benza R, Corris P, Klinger J, Langleben D, Naeije R, Simonneau G, Vizza CD, Halank M, Church A, Coghlan JG, Chang M, Colorado P, Meier C, Busse D, Hoeper M. The Relationship of Hemodynamics and Exercise Capacity With Response to Riociguat Therapy in the Respite Study of PAH Patients With an Insufficient Response to Phosphodiesterase 5 Inhibitors Chest. 152. DOI: 10.1016/J.Chest.2017.08.1038 |
0.289 |
|
| 2012 |
Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. Bmj (Clinical Research Ed.). 345: e7498. PMID 23150473 DOI: 10.1136/Bmj.E7498 |
0.281 |
|
| 2009 |
Looper KJ, Pierre A, Dunkley DM, Sigal JJ, Langleben D. Depressive symptoms in relation to physical functioning in pulmonary hypertension. Journal of Psychosomatic Research. 66: 221-5. PMID 19232234 DOI: 10.1016/j.jpsychores.2008.09.014 |
0.28 |
|
| 2022 |
Langleben D, Fox BD, Orfanos SE, Giovinazzo M, Catravas JD. Pulmonary capillary recruitment and distention in mammalian lungs: species similarities. European Respiratory Review : An Official Journal of the European Respiratory Society. 31. PMID 35197268 DOI: 10.1183/16000617.0248-2021 |
0.279 |
|
| 1990 |
Langleben D, Moroz LA, Schlesinger RD. Cellular-phase fibrinolysis and coronary reperfusion during acute myocardial infarction: A study in patients receiving intravenous streptokinase-methylprednisoline therapy Thrombosis Research. 59: 247-258. PMID 2237810 DOI: 10.1016/0049-3848(90)90128-Y |
0.278 |
|
| 1986 |
Moroz LA, MacLean LD, Langleben D. Abnormalities in the cellular phase of blood fibrinolytic activity in systemic lupus erythematosus and in venous thromboembolism. Thrombosis Research. 43: 595-602. PMID 3764806 DOI: 10.1016/0049-3848(86)90096-4 |
0.274 |
|
| 1991 |
Langleben D, Moroz LA. Interspecies Variation in the Cellular Phase of Blood Fibrinolytic Activity Experimental Biology and Medicine. 196: 270-272. PMID 1998003 DOI: 10.3181/00379727-196-43187 |
0.251 |
|
| 1985 |
Langleben D, Moroz LA. Participation of blood cells in exercise-induced fibrinolysis. Thrombosis Research. 39: 733-740. PMID 2934862 DOI: 10.1016/0049-3848(85)90257-9 |
0.246 |
|
| 1989 |
Langleben D, Wolkove N, Srolovitz H, Billick RC, Sheiner NM. Hemothorax and Hemopericardium in a Patient with Bean's Blue Rubber Bleb Nevus Syndrome Chest. 95: 1352-1353. PMID 2721277 DOI: 10.1378/Chest.95.6.1352 |
0.244 |
|
| 2018 |
Benza RL, Corris PA, Klinger JR, Langleben D, Naeije R, Simonneau G, Vizza C, Wirtz H, Patarroyo-Aponte M, Chang M, Colorado P, Meier C, Busse D, Hoeper MM. Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function Journal of Heart and Lung Transplantation. 37. DOI: 10.1016/J.Healun.2018.01.368 |
0.241 |
|
| 1991 |
Stewart DJ, Langleben D, Cernacek P, Cianflone K. Endothelin release is inhibited by coculture of endothelial cells with cells of vascular media. The American Journal of Physiology. 259: H1928-32. PMID 2260717 DOI: 10.1152/Ajpheart.1990.259.6.H1928 |
0.239 |
|
| 2020 |
Vassiliou AG, Keskinidou C, Kotanidou A, Frantzeskaki F, Dimopoulou I, Langleben D, Orfanos SE. Decreased bone morphogenetic protein type II receptor and BMP-related signalling molecules' expression in aquaporin 1-silenced human pulmonary microvascular endothelial cells. Hellenic Journal of Cardiology : Hjc = Hellenike Kardiologike Epitheorese. 62: 84-86. PMID 32304816 DOI: 10.1016/j.hjc.2020.04.003 |
0.216 |
|
| 2014 |
Kolettis TM, Barton M, Langleben D, Matsumura Y. Endothelin in coronary artery disease and myocardial infarction. Cardiology in Review. 21: 249-56. PMID 23422018 DOI: 10.1097/CRD.0b013e318283f65a |
0.205 |
|
| 2014 |
Langleben D. EditorialsPulmonary Capillary Hemangiomatosis: The Puzzle Takes Shape Chest. 145. PMID 24493495 DOI: 10.1378/Chest.13-2513 |
0.203 |
|
| 2004 |
Mortazavi A, Eisenberg MJ, Langleben D, Ernst P, Schiff RL. Altitude-related hypoxia: risk assessment and management for passengers on commerical aircraft. Aviation, Space, and Environmental Medicine. 74: 922-7. PMID 14503669 |
0.199 |
|
| 1996 |
Khoury J, Langleben D. Platelet-activating factor stimulates lung pericyte growth in vitro American Journal of Physiology - Lung Cellular and Molecular Physiology. 270. PMID 8780000 |
0.197 |
|
| 1992 |
Lockhat D, Langleben D, Zidulka A. Hemodynamic differences between continual positive and two types of negative pressure ventilation. The American Review of Respiratory Disease. 146: 677-80. PMID 1519847 DOI: 10.1164/ajrccm/146.3.677 |
0.186 |
|
| 1987 |
Davies P, Smith BT, Maddalo FB, Langleben D, Tobias D, Fujiwara K, Reid L. Characteristics of lung pericytes in culture including their growth inhibition by endothelial substrate Microvascular Research. 33: 300-314. PMID 3039313 DOI: 10.1016/0026-2862(87)90025-2 |
0.159 |
|
| 1990 |
Langleben D. Atherosclerosis and the lung. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 142: 139. PMID 2295032 |
0.147 |
|
| 1990 |
Langleben D. Atherosclerosis and the lung. The Canadian Journal of Cardiology. 6: VI. PMID 2224612 |
0.147 |
|
| 2012 |
Azoulay L, Dell'Aniello S, Simon TA, Langleben D, Renoux C, Suissa S. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: A nested case-control study Bmc Cardiovascular Disorders. 12. PMID 22734842 DOI: 10.1186/1471-2261-12-49 |
0.123 |
|
| 2014 |
Taveira TH, Wu WC, Tschibelu E, Borsook D, Simonson DC, Yamamoto R, Langleben DD, Swift R, Elman I. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study. Journal of Psychopharmacology (Oxford, England). 28: 395-400. PMID 24218048 DOI: 10.1177/0269881113509904 |
0.118 |
|
| 2019 |
Shi Z, Jagannathan K, Wang AL, Fairchild VP, Lynch KG, Suh JJ, Childress AR, Langleben DD. Behavioral and accumbal responses during an affective Go/No-go task predict adherence to injectable naltrexone treatment in opioid use disorder. The International Journal of Neuropsychopharmacology. PMID 30690502 DOI: 10.1093/ijnp/pyz002 |
0.096 |
|
| 2016 |
Constance C, Trudeau L, Jolicoeur EM, Langleben D, Rivard A, Chehayeb R, Côté MA, Delgado D. Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. PMID 27909345 DOI: 10.1038/leu.2016.336 |
0.088 |
|
| 2008 |
Langleben DD, Ruparel K, Elman I, Busch-Winokur S, Pratiwadi R, Loughead J, O'Brien CP, Childress AR. Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. The American Journal of Psychiatry. 165: 390-4. PMID 18056224 DOI: 10.1176/appi.ajp.2007.07010070 |
0.088 |
|
| 2009 |
Suh JJ, Langleben DD, Ehrman RN, Hakun JG, Wang Z, Li Y, Busch SI, O'Brien CP, Childress AR. Low prefrontal perfusion linked to depression symptoms in methadone-maintained opiate-dependent patients. Drug and Alcohol Dependence. 99: 11-7. PMID 18674871 DOI: 10.1016/J.Drugalcdep.2008.06.007 |
0.087 |
|
| 2002 |
Langleben DD, Acton PD, Austin G, Elman I, Krikorian G, Monterosso JR, Portnoy O, Ridlehuber HW, Strauss HW. Effects of methylphenidate discontinuation on cerebral blood flow in prepubescent boys with attention deficit hyperactivity disorder. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 43: 1624-9. PMID 12468511 |
0.085 |
|
| 2002 |
Langleben DD, Austin G, Krikorian G, Ridlehuber HW, Goris ML, Strauss HW. Interhemispheric asymmetry of regional cerebral blood flow in prepubescent boys with attention deficit hyperactivity disorder. Nuclear Medicine Communications. 22: 1333-40. PMID 11711904 DOI: 10.1097/00006231-200112000-00009 |
0.082 |
|
| 2023 |
Li X, Langleben DD, Lynch KG, Wang GJ, Elman I, Wiers CE, Shi Z. Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence. Frontiers in Psychiatry. 14: 1247961. PMID 37599869 DOI: 10.3389/fpsyt.2023.1247961 |
0.082 |
|
| 2021 |
Langleben D, Berkson L, Chartrand S. Selexipag Therapy for Raynaud Phenomenon-induced Severe Digital Ischemia in Intravenous Epoprostenol Responders With Connective Tissue Disease. The Journal of Rheumatology. 48: 616-617. PMID 34237010 DOI: 10.3899/jrheum.200716 |
0.079 |
|
| 2003 |
Szobot CM, Ketzer C, Cunha RD, Parente MA, Langleben DD, Acton PD, Kapczinski F, Rohde LA. The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder. European Journal of Nuclear Medicine and Molecular Imaging. 30: 423-6. PMID 12634972 DOI: 10.1007/S00259-002-1082-0 |
0.076 |
|
| 2009 |
Hakun JG, Ruparel K, Seelig D, Busch E, Loughead JW, Gur RC, Langleben DD. Towards clinical trials of lie detection with fMRI. Social Neuroscience. 4: 518-27. PMID 18633835 DOI: 10.1080/17470910802188370 |
0.075 |
|
| 2017 |
Wang AL, Lowen SB, Elman I, Shi Z, Fairchild VP, Bouril A, Gur RC, Langleben DD. Sustained opioid antagonism modulates striatal sensitivity to baby schema in opioid use disorder. Journal of Substance Abuse Treatment. PMID 29146290 DOI: 10.1016/J.Jsat.2017.10.007 |
0.072 |
|
| 2004 |
Elman I, Rott D, Green AI, Langleben DD, Lukas SE, Goldstein DS, Breier A. Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. Psychopharmacology. 176: 369-75. PMID 15179540 DOI: 10.1007/S00213-004-1890-Y |
0.069 |
|
| 2021 |
Shi Z, Langleben DD, O'Brien CP, Childress AR, Wiers CE. Multivariate pattern analysis links drug use severity to distributed cortical hypoactivity during emotional inhibitory control in opioid use disorder. Neuroimage. Clinical. 32: 102806. PMID 34525436 DOI: 10.1016/j.nicl.2021.102806 |
0.068 |
|
| 2005 |
Langleben DD, Loughead JW, Bilker WB, Ruparel K, Childress AR, Busch SI, Gur RC. Telling truth from lie in individual subjects with fast event-related fMRI. Human Brain Mapping. 26: 262-72. PMID 16161128 DOI: 10.1002/Hbm.20191 |
0.067 |
|
| 2016 |
Guina J, Gupta A, Langleben DD, Elman I. Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder. The Journal of Clinical Psychiatry. 77: e1650-e1651. PMID 28086013 DOI: 10.4088/JCP.16l10705 |
0.065 |
|
| 2017 |
Guina J, Roy S, Gupta A, Langleben DD, Elman I. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration. Human Psychopharmacology. PMID 28573760 DOI: 10.1002/hup.2604 |
0.065 |
|
| 2014 |
Langleben DD. Focus on addiction: Buspirone for cocaine relapse and monitoring controlled substances prescribed to dually diagnosed patients. The Journal of Clinical Psychiatry. 75: 748-9. PMID 25093471 DOI: 10.4088/JCP.14f09279 |
0.063 |
|
| 2006 |
Langleben DD, Monterosso J, Elman I, Ash B, Krikorian G, Austin G. Effect of methylphenidate on Stroop Color-Word task performance in children with attention deficit hyperactivity disorder. Psychiatry Research. 141: 315-20. PMID 16516306 DOI: 10.1016/j.psychres.2005.09.007 |
0.061 |
|
| 2001 |
Krausz Y, Ikeda DM, Jadvar H, Langleben D, Birdwell R, Strauss HW. Non-visualization of sentinel lymph node in patients with breast cancer. Nuclear Medicine Communications. 22: 25-32. PMID 11233548 DOI: 10.1097/00006231-200101000-00004 |
0.06 |
|
| 2002 |
Langleben DD, Schroeder L, Maldjian JA, Gur RC, McDonald S, Ragland JD, O'Brien CP, Childress AR. Brain activity during simulated deception: an event-related functional magnetic resonance study. Neuroimage. 15: 727-32. PMID 11848716 DOI: 10.1006/Nimg.2001.1003 |
0.057 |
|
| 2019 |
Chao G, Sun J, Lu J, Wang AL, Langleben DD, Li CS, Bi J. Multi-View Cluster Analysis with Incomplete Data to Understand Treatment Effects. Information Sciences. 494: 278-293. PMID 32863420 DOI: 10.1016/j.ins.2019.04.039 |
0.057 |
|
| 2015 |
Wang AL, Elman I, Lowen SB, Blady SJ, Lynch KG, Hyatt JM, O'Brien CP, Langleben DD. Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence. Translational Psychiatry. 5: e531. PMID 25781230 DOI: 10.1038/tp.2015.20 |
0.056 |
|
| 2018 |
Shi Z, Wang AL, Jagannathan K, Fairchild VP, O'Brien CP, Childress AR, Langleben DD. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder. Journal of Psychiatry & Neuroscience : Jpn. 43: 254-261. PMID 29947607 DOI: 10.1503/jpn.170036 |
0.056 |
|
| 2018 |
Shi Z, Wang AL, Jagannathan K, Fairchild VP, O'Brien CP, Childress AR, Langleben DD. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder. Journal of Psychiatry & Neuroscience : Jpn. 43: 170036. PMID 29485031 DOI: 10.1503/jpn.170036 |
0.056 |
|
| 2014 |
Langleben DD, Ruparel K, Elman I, Loughead JW, Busch EL, Cornish J, Lynch KG, Nuwayser ES, Childress AR, O'Brien CP. Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients. Addiction Biology. 19: 262-71. PMID 22747521 DOI: 10.1111/j.1369-1600.2012.00462.x |
0.056 |
|
| 2005 |
Bloomer CW, Langleben DD, Meyerhoff DJ. Magnetic resonance detects brainstem changes in chronic, active heavy drinkers. Psychiatry Research. 132: 209-18. PMID 15664792 DOI: 10.1016/j.pscychresns.2004.06.003 |
0.055 |
|
| 2019 |
Krupitsky E, Blokhina E, Zvartau E, Verbitskaya E, Lioznov D, Yaroslavtseva T, Palatkin V, Vetrova M, Bushara N, Burakov A, Masalov D, Mamontova O, Langleben D, Poole S, Gross R, et al. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. The Lancet. Hiv. PMID 30880163 DOI: 10.1016/S2352-3018(18)30362-X |
0.055 |
|
| 2008 |
Hakun JG, Seelig D, Ruparel K, Loughead JW, Busch E, Gur RC, Langleben DD. fMRI investigation of the cognitive structure of the Concealed Information Test. Neurocase. 14: 59-67. PMID 18569732 DOI: 10.1080/13554790801992792 |
0.05 |
|
| 2016 |
Langleben DD, Hakun JG, Seelig D, Wang AL, Ruparel K, Bilker WB, Gur RC. Polygraphy and functional magnetic resonance imaging in lie detection: a controlled blind comparison using the concealed information test. The Journal of Clinical Psychiatry. PMID 26794034 DOI: 10.4088/Jcp.15M09785 |
0.05 |
|
| 2020 |
James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer? Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 31986520 DOI: 10.1038/S41386-020-0619-X |
0.05 |
|
| 2009 |
Yamamoto R, Ariely D, Chi W, Langleben DD, Elman I. Gender differences in the motivational processing of babies are determined by their facial attractiveness. Plos One. 4: e6042. PMID 19554100 DOI: 10.1371/Journal.Pone.0006042 |
0.049 |
|
| 2017 |
Shi Z, Wang AL, Aronowitz CA, Romer D, Langleben DD. Individual differences in the processing of smoking-cessation video messages: An imaging genetics study. Biological Psychology. 128: 125-131. PMID 28757070 DOI: 10.1016/J.Biopsycho.2017.07.019 |
0.047 |
|
| 2017 |
Todd Milne G, Sandner P, Lincoln KA, Harrison PC, Chen H, Wang H, Clifford H, Qian HS, Wong D, Sarko C, Fryer R, Richman J, Reinhart GA, Boustany CM, Pullen SS, ... ... Langleben D, ... ... Langleben D, et al. Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications : Bamberg, Germany. 23-25 June, 2017. Bmc Pharmacology & Toxicology. 18: 64. PMID 29035170 DOI: 10.1186/s40360-017-0170-5 |
0.047 |
|
| 2009 |
Langleben DD, Dattilio FM. Commentary: the future of forensic functional brain imaging. The Journal of the American Academy of Psychiatry and the Law. 36: 502-4. PMID 19092068 |
0.047 |
|
| 2015 |
Wang AL, Romer D, Elman I, Turetsky BI, Gur RC, Langleben DD. Emotional graphic cigarette warning labels reduce the electrophysiological brain response to smoking cues. Addiction Biology. 20: 368-76. PMID 24330194 DOI: 10.1111/Adb.12117 |
0.047 |
|
| 2005 |
Wolpe PR, Foster KR, Langleben DD. Emerging neurotechnologies for lie-detection: promises and perils. The American Journal of Bioethics : Ajob. 5: 39-49. PMID 16036700 DOI: 10.1080/15265160590923367 |
0.045 |
|
| 2012 |
Langleben DD, Busch EL, O'Brien CP, Elman I. Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence. Psychopharmacology. 220: 559-64. PMID 21960180 DOI: 10.1007/s00213-011-2503-1 |
0.043 |
|
| 2024 |
Shi Z, Wang AL, Audrain-McGovern J, Lynch KG, Loughead J, Langleben DD. Delayed effects of cigarette graphic warning labels on smoking behavior. Medrxiv : the Preprint Server For Health Sciences. PMID 38260670 DOI: 10.1101/2024.01.06.24300835 |
0.042 |
|
| 2009 |
Glocker ML, Langleben DD, Ruparel K, Loughead JW, Valdez JN, Griffin MD, Sachser N, Gur RC. Baby schema modulates the brain reward system in nulliparous women. Proceedings of the National Academy of Sciences of the United States of America. 106: 9115-9. PMID 19451625 DOI: 10.1073/Pnas.0811620106 |
0.041 |
|
| 2008 |
Rott D, Langleben DD, Elman I. Cocaine decreases plasma insulin concentrations in non-diabetic subjects: a randomized double-blind study. Diabetic Medicine : a Journal of the British Diabetic Association. 25: 510-1. PMID 18346162 DOI: 10.1111/j.1464-5491.2008.02412.x |
0.041 |
|
| 2018 |
Elman I, Upadhyay J, Langleben DD, Albanese M, Becerra L, Borsook D. Reward and aversion processing in patients with post-traumatic stress disorder: functional neuroimaging with visual and thermal stimuli. Translational Psychiatry. 8: 240. PMID 30389908 DOI: 10.1038/S41398-018-0292-6 |
0.041 |
|
| 2020 |
Shi Z, Jagannathan K, Padley JH, Wang AL, Fairchild VP, O'Brien CP, Childress AR, Langleben DD. The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder. Addiction Biology. e12977. PMID 33098179 DOI: 10.1111/adb.12977 |
0.04 |
|
| 2021 |
Fragale JE, James MH, Avila JA, Spaeth AM, Aurora RN, Langleben D, Aston-Jones G. The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System. Frontiers of Neurology and Neuroscience. 45: 117-127. PMID 34052815 DOI: 10.1159/000514965 |
0.039 |
|
| 2009 |
Langleben DD, Loughead JW, Ruparel K, Hakun JG, Busch-Winokur S, Holloway MB, Strasser AA, Cappella JN, Lerman C. Reduced prefrontal and temporal processing and recall of high "sensation value" ads. Neuroimage. 46: 219-25. PMID 19457412 DOI: 10.1016/J.Neuroimage.2008.12.062 |
0.038 |
|
| 2021 |
Wang AL, Shulman M, Choo TH, Pavlicova M, Langleben DD, Nunes EV, Rotrosen J. Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD. Addiction Biology. e13112. PMID 34877769 DOI: 10.1111/adb.13112 |
0.038 |
|
| 2005 |
Davatzikos C, Ruparel K, Fan Y, Shen DG, Acharyya M, Loughead JW, Gur RC, Langleben DD. Classifying spatial patterns of brain activity with machine learning methods: application to lie detection. Neuroimage. 28: 663-8. PMID 16169252 DOI: 10.1016/J.Neuroimage.2005.08.009 |
0.037 |
|
| 2020 |
Wang AL, Shi Z, Elman I, Langleben DD. Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder. The American Journal of Drug and Alcohol Abuse. 1-6. PMID 32379516 DOI: 10.1080/00952990.2020.1741001 |
0.036 |
|
| 2023 |
Todaro DR, Li X, Pereira-Rufino LS, Manza P, Nasrallah IM, Das S, Childress AR, Kranzler HR, Volkow ND, Langleben DD, Shi Z, Wiers CE. Hippocampal volume loss in individuals with a history of non-fatal opioid overdose. Addiction Biology. 28: e13336. PMID 37753562 DOI: 10.1111/adb.13336 |
0.036 |
|
| 2013 |
Romer D, Peters E, Strasser AA, Langleben D. Desire versus efficacy in smokers' paradoxical reactions to pictorial health warnings for cigarettes. Plos One. 8: e54937. PMID 23383006 DOI: 10.1371/Journal.Pone.0054937 |
0.036 |
|
| 2016 |
Regier PS, Monge ZA, Franklin TR, Wetherill RR, Teitelman A, Jagannathan K, Suh JJ, Wang Z, Young KA, Gawrysiak M, Langleben DD, Kampman KM, O'Brien CP, Childress AR. Emotional, physical and sexual abuse are associated with a heightened limbic response to cocaine cues. Addiction Biology. PMID 27654662 DOI: 10.1111/Adb.12445 |
0.034 |
|
| 2021 |
Regier PS, Jagannathan K, Franklin TR, Wetherill RR, Langleben DD, Gawyrsiak M, Kampman KM, Childress AR. Sustained brain response to repeated drug cues is associated with poor drug-use outcomes. Addiction Biology. e13028. PMID 33634928 DOI: 10.1111/adb.13028 |
0.034 |
|
| 2017 |
Parcianello RR, Mardini V, Ceresér KMM, Langleben DD, Xavier F, Zavaschi MLS, Rhode LAP, Pechansky F, Gubert C, Szobot CM. Increased cocaine and amphetamine-regulated transcript cord blood levels in the newborns exposed to crack cocaine in utero. Psychopharmacology. PMID 29080905 DOI: 10.1007/s00213-017-4759-6 |
0.031 |
|
| 2009 |
Glocker ML, Langleben DD, Ruparel K, Loughead JW, Gur RC, Sachser N. Baby Schema in Infant Faces Induces Cuteness Perception and Motivation for Caretaking in Adults. Ethology : Formerly Zeitschrift Fur Tierpsychologie. 115: 257-263. PMID 22267884 DOI: 10.1111/J.1439-0310.2008.01603.X |
0.03 |
|
| 2015 |
Wang AL, Lowen SB, Romer D, Giorno M, Langleben DD. Emotional reaction facilitates the brain and behavioural impact of graphic cigarette warning labels in smokers. Tobacco Control. 24: 225-32. PMID 25564288 DOI: 10.1136/Tobaccocontrol-2014-051993 |
0.029 |
|
| 2013 |
Wang AL, Ruparel K, Loughead JW, Strasser AA, Blady SJ, Lynch KG, Romer D, Cappella JN, Lerman C, Langleben DD. Content matters: neuroimaging investigation of brain and behavioral impact of televised anti-tobacco public service announcements. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 7420-7. PMID 23616548 DOI: 10.1523/Jneurosci.3840-12.2013 |
0.029 |
|
| 2023 |
Shi Z, Li X, Byanyima JI, O'Brien CP, Childress AR, Lynch KG, Loughead J, Wiers CE, Langleben DD. Effects of current smoking severity on brain gray matter volume in opioid use disorder - a voxel-based morphometry study. The American Journal of Drug and Alcohol Abuse. 1-10. PMID 36787540 DOI: 10.1080/00952990.2023.2169616 |
0.028 |
|
| 2008 |
Childress AR, Ehrman RN, Wang Z, Li Y, Sciortino N, Hakun J, Jens W, Suh J, Listerud J, Marquez K, Franklin T, Langleben D, Detre J, O'Brien CP. Prelude to passion: limbic activation by "unseen" drug and sexual cues. Plos One. 3: e1506. PMID 18231593 DOI: 10.1371/Journal.Pone.0001506 |
0.027 |
|
| 2023 |
Shi Z, Li X, Kampman KM, Childress AR, Wiers CE, Langleben DD. Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder. The Journal of Clinical Psychiatry. 84. PMID 37074295 DOI: 10.4088/JCP.22br14567 |
0.023 |
|
| 2018 |
Wang AL, Shi Z, Fairchild VP, Aronowitz CA, Langleben DD. Emotional salience of the image component facilitates recall of the text of cigarette warning labels. European Journal of Public Health. PMID 29718188 DOI: 10.1093/eurpub/cky059 |
0.023 |
|
| 2000 |
Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 41: 1861-7. PMID 11079496 |
0.022 |
|
| 2019 |
Shi Z, Wang AL, Aronowitz CA, Cappella JN, Romer D, Langleben DD. Connectivity between visual and auditory cortices mediates the influence of argument strength on the effectiveness of smoking-cessation videos among smokers low in sensation seeking. Psychology Research and Behavior Management. 12: 531-542. PMID 31410074 DOI: 10.2147/Prbm.S183394 |
0.021 |
|
| 2022 |
Shi Z, Wang AL, Fairchild VP, Aronowitz CA, Padley JH, Lynch KG, Loughead J, Langleben DD. Effects of emotional arousal on the neural impact and behavioral efficacy of cigarette graphic warning labels. Addiction (Abingdon, England). PMID 36562154 DOI: 10.1111/add.16112 |
0.021 |
|
| 2016 |
Wang AL, Lowen SB, Shi Z, Bissey B, Metzger DS, Langleben DD. Targeting modulates audiences' brain and behavioral responses to safe sex video ads. Social Cognitive and Affective Neuroscience. PMID 27217112 DOI: 10.1093/scan/nsw070 |
0.02 |
|
| 2014 |
Seelig D, Wang AL, Jaganathan K, Loughead JW, Blady SJ, Childress AR, Romer D, Langleben DD. Low message sensation health promotion videos are better remembered and activate areas of the brain associated with memory encoding. Plos One. 9: e113256. PMID 25409187 DOI: 10.1371/journal.pone.0113256 |
0.019 |
|
| 2015 |
Langleben DD. Buprenorphine-naloxone treatment of prescription opioid abuse: does past performance predict future results? The Journal of Clinical Psychiatry. 76: 195-7. PMID 25742206 DOI: 10.4088/JCP.14com09617 |
0.018 |
|
| 2006 |
Platek SM, Loughead JW, Gur RC, Busch S, Ruparel K, Phend N, Panyavin IS, Langleben DD. Neural substrates for functionally discriminating self-face from personally familiar faces. Human Brain Mapping. 27: 91-8. PMID 16035037 DOI: 10.1002/Hbm.20168 |
0.016 |
|
| 2013 |
Langleben DD, Moriarty JC. Using Brain Imaging for Lie Detection: Where Science, Law and Research Policy Collide. Psychology, Public Policy, and Law : An Official Law Review of the University of Arizona College of Law and the University of Miami School of Law. 19: 222-234. PMID 23772173 DOI: 10.1037/a0028841 |
0.013 |
|
| 2018 |
Fairchild VP, Aronowitz CA, Langleben DD, Wang AL. Brain Responses to Anti-Smoking Health Warnings In Youth. Current Addiction Reports. 5: 372-378. PMID 31396471 DOI: 10.1007/s40429-018-0221-z |
0.013 |
|
| 2016 |
Shi Z, Wang AL, Langleben DD. Playing it safe: a video game probing the relationship between addiction, gender, and avoidance. The Journal of Clinical Psychiatry. 77: 395-397. PMID 27046311 DOI: 10.4088/JCP.16com10752 |
0.01 |
|
| 2021 |
Shi Z, Wang AL, Fairchild VP, Aronowitz CA, Lynch KG, Loughead J, Langleben DD. Addicted to green: priming effect of menthol cigarette packaging on brain response to smoking cues. Tobacco Control. PMID 34599084 DOI: 10.1136/tobaccocontrol-2021-056639 |
0.01 |
|
| 2014 |
Romer D, Jamieson PE, Bushman BJ, Bleakley A, Wang A, Langleben D, Jamieson KH. Parental desensitization to violence and sex in movies. Pediatrics. 134: 877-84. PMID 25332494 DOI: 10.1542/Peds.2014-1167 |
0.01 |
|
| 2013 |
Moriarty JC, Langleben DD, Provenzale JM. Brain trauma, PET scans and forensic complexity. Behavioral Sciences & the Law. 31: 702-20. PMID 24132788 DOI: 10.1002/bsl.2089 |
0.01 |
|
| 2010 |
Wolpe PR, Foster KR, Langleben DD. Emerging neurotechnologies for lie-detection: promises and perils. The American Journal of Bioethics : Ajob. 10: 40-8. PMID 20945266 DOI: 10.1080/15265161.2010.519238 |
0.01 |
|
| Hide low-probability matches. |